I���T ’ S C���D
THINK
* PAXLOVID is indicated in patients ≥ 18 years with mild-moderate COVID-19 , unless contraindicated . Review for drug-drug interactions . Commence within 5 days of symptom onset . 1 PBS restrictions apply . 2
The
First-line oral COVID-19 antiviral treatment unless contraindicated , as required by PBS criteria 2 – 4
Contraindications can be found using the University of Liverpool Drug Interactions Checker or PAXLOVID Product Information . 1 , 5
Similar rates of adverse events vs placebo 1 , 6 ‡
‡
Incidence of treatment-emergent AEs were similar between PAXLOVID ( 22.6 %) and placebo ( 23.9 %), and mostly mild or moderate . The most common side effects included dysgeusia , diarrhoea , and vomiting , which were mild or moderate and resolved . 6
With proven efficacy :
86 % reduction in COVID-19-related hospitalisation or death 1 , 6 †
†
When taken within 5 days of symptom onset in patients with at least one risk factor for severe COVID-19 illness . Efficacy compared with placebo through Day 28 in the EPIC-HR clinical trial ( P < 0.001 ; secondary endpoint ) 1 , 6
Dosage and Administration : Recommended dose 300 mg nirmatrelvir and 100 mg ritonavir tablets OR 150 mg nirmatrelvir and 100 mg ritonavir in moderate renal impairment , taken together orally every 12 hours for 5 days . 1
Before prescribing , please review full product information available at pfi . sr / paxlovid-pi
For more information about the PAXLOVID PBS criteria , scan the QR code
This medicinal product is subject to additional monitoring in Australia . This will allow quick identifi cation of new safety information . Healthcare professionals are asked to report any suspected adverse events at www . tga . gov . au / reporting-problems .
Alternatively , any adverse events which are experienced with PAXLOVID ® can be reported to Pfi zer on 1800 675 229 or by email to AUS . AEReporting @ pfi zer . com
Warning : Nirmatrelvir with ritonavir has signifi cant drug-drug interactions . Prescribers and dispensers should carefully review a patient ’ s concomitant medications .
PBS Information : Authority Required ( STREAMLINED ). Category : GENERAL – General Schedule ( Code GE ). For verifi ed SARS-CoV-2 infection . Treatment must be initiated within 5 days of symptom onset . Refer to PBS Schedule for full authority information .